Venus Remedies secures Ukrainian GMP renewal

Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards

Biocon gets six-month extension on insulin supply pact in Malaysia

The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025

Astellas and Pfizer’s XTANDI shows overall survival in metastatic hormone-sensitive prostate cancer

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%

Mankind Pharma posts Q4 FY25 consolidated PAT Rs. 425.11 Cr

The company has posted net profit of Rs. 1,986.43 crores for the Financial Year ended March 31, 2025

Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8

Venus Remedies joins United Nations Global Compact

This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery

Lupin to use Honeywell’s HFO technology in inhalers

Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants

Tata 1mg optimises e-commerce operations with Unicommerce

Zydus Wellness records a growth of 30% in net profit in FY25

EBITDA for the period rose by 23.2% to Rs. 3,797 million

Global Health posts Q4 FY25 consolidated PAT at Rs. 101.4 Cr

Global Health has posted net profit of Rs. 481.43 crores for the Financial Year ended March 31, 2025